Position in NVS
as of Jun 30, 2026
· filed Aug 12, 2026
Position Value
$293,066
+$7,424 QoQ
Shares Held
1,870
0.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#1,145
of 1,603 holders
Holding Since
Jun 2024
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026SMITH, MOORE & CO. holds $27,430,178 across 9 Drug Manufacturers - General names. NVS ranks #9 (1.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ABBV |
AbbVie Inc.
|
28,543 | $7,182,560 | |
| 2 | LLY |
ELI LILLY & Co
|
5,912 | $7,091,030 | |
| 3 | JNJ |
Johnson & Johnson
|
23,180 | $5,887,024 | |
| 4 | MRK |
Merck & Co., Inc.
|
23,976 | $3,080,916 | |
| 5 | AMGN |
Amgen Inc
|
4,729 | $1,712,465 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
15,730 | $906,362 | |
| 7 | PFE |
Pfizer Inc
|
32,201 | $775,400 | |
| 8 | AZN |
Astrazeneca PLC
|
2,644 | $501,355 |
All Filings in NVS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $293,066 | 1,870 | Shares | Sole | 2026-08-12 | |
| 2026-03-31 | $285,642 | 1,870 | Shares | Sole | 2026-05-05 | |
| 2025-12-31 | $274,223 | 1,989 | Shares | Sole | 2026-01-23 | |
| 2025-09-30 | $255,069 | 1,989 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $236,574 | 1,955 | Shares | Sole | 2025-08-13 | |
| 2025-03-31 | $217,051 | 1,947 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $216,417 | 2,224 | Shares | Sole | 2025-02-13 | |
| 2024-09-30 | $223,943 | 1,947 | Shares | Sole | 2024-11-12 | |
| 2024-06-30 | $207,277 | 1,947 | Shares | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||